Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $33
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $33
Chardan Capital維持對eyepoint pharmaceuticals的買入評級，並將目標股價上調至33美元
Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and raises the price target from $28 to $33.
Chardan Capital分析師Daniil Gataulin維持對納斯達克：EYPT的eyepoint pharmaceuticals買入評級，並將目標股價從28美元上調至33美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間